GlassScriptPhysician profile
Somaira Nowsheen
NPI 1003445610
$15,290.04
in general payments reported to CMS, 2019-2025
27 companies · $2,046 in 2025
The $2,046 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $240 · 2022: $8,212 · 2023: $1,941 · 2024: $2,851 · 2025: $2,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,907 · Travel and Lodging: $753 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,906.64 |
| Travel and Lodging | $752.68 |
| Education | $178.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $7,457.20 | 2022-2025 | Spevigo |
| Abbvie INC. | $1,492.21 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $781.19 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $675.55 | 2024-2025 | Tremfya |
| Ucb, INC. | $564.04 | 2024-2025 | Bimzelx |
| Allergan, INC. | $531.06 | 2022 | |
| Incyte Corporation | $521.31 | 2023-2024 | Opzelura |
| Genzyme Corporation | $470.87 | 2022-2025 | |
| Dermavant Sciences, INC. | $440.79 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $347.97 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $295.80 | 2024-2025 | Dupixent, Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $284.43 | 2021-2022 | |
| Amgen INC. | $208.73 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $194.86 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $165.83 | 2023-2025 | Tremfya |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $163.65 | 2024-2025 | Nemluvio |
| Lilly USA, LLC | $142.36 | 2025 | Ebglyss, Taltz |
| Leo Pharma INC. | $121.83 | 2023 | Adbry |
| Regeneron Pharmaceuticals, INC. | $108.96 | 2023 | Libtayo |
| Pfizer INC. | $81.31 | 2023 | |
| Arcutis Biotherapeutics, INC. | $62.95 | 2025 | Zoryve |
| Organon LLC | $39.97 | 2025 | Vtama |
| Botanix Sb INC | $35.17 | 2025 | Sofdra |
| Epi Health, LLC | $35.00 | 2022 | |
| Organogenesis INC. | $26.22 | 2025 | Cygnus Dual |
| Lnhc, INC | $21.38 | 2025 | Zelsuvmi |
| Strata Skin Sciences, INC. | $19.40 | 2025 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Somaira Nowsheen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.